Table 1 Frequencies of people with disturbed levels of anti-melanin and anti-tyrosinase autoantibodies
From: Immunity to melanin and to tyrosinase in melanoma patients, and in people with vitiligo
Healthy control people | People with vitiligo | Melanoma patients | Melanoma patients (without metastases) | Melanoma patients (with metastases) | |
|---|---|---|---|---|---|
Increased anti-melanin IgM | 7 (32) | 2 (16) | 3 (62) | 3 (27) | 0 (35) |
Decreased anti-melanin IgM | 4 (32) | 2 (16) | 11 (62) | 4 (27) | 7 (35) |
Increased anti-melanin IgA | 5 (32) | 0 (16) | 22 (62) | 7 (27) | 15 (35) |
Decreased anti-melanin IgA | 2 (32) | 1 (16) | 13 (62) | 5 (27) | 8 (35) |
Increased anti-melanin IgG | 7 (32) | 3 (16) | 13 (62) | 9 (27) | 4 (35) |
Decreased anti-melanin IgG | 5 (32) | 5 (16) | 6 (62) | 2 (27) | 4 (35) |
Increased anti-tyrosinase IgM | 7 (30) | 0 (16) | 0 (62) | 0 (26) | 0 (36) |
Decreased anti-tyrosinase IgM | 3 (30) | 3 (16) | 28 (62) | 4 (26) | 24 (36) |
Increased anti-tyrosinase IgA | 5 (29) | 0 (16) | 14 (62) | 3 (26) | 11 (36) |
Decreased anti-tyrosinase IgA | 2 (29) | 0 (16) | 2 (62) | 0 (26) | 2 (36) |
Increased anti-tyrosinase IgG | 8 (29) | 1 (16) | 7 (62) | 2 (26) | 5 (36) |
Decreased anti-tyrosinase IgG | 1 (29) | 1 (16) | 5 (62) | 2 (26) | 3 (36) |